Programmed cell removal by calreticulin in tissue homeostasis and cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed cell removal by calreticulin in tissue homeostasis and cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-06
DOI
10.1038/s41467-018-05211-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Unifying mechanism for different fibrotic diseases
- (2017) Gerlinde Wernig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Both the apoptotic suicide pathway and phagocytosis are required for a programmed cell death in Caenorhabditis elegans
- (2016) Holly L. Johnsen et al. BMC BIOLOGY
- Training the next generation of biomedical investigators in glycosciences
- (2016) Peter Agre et al. JOURNAL OF CLINICAL INVESTIGATION
- CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
- (2016) Yoko Kojima et al. NATURE
- Single-cell analysis of mixed-lineage states leading to a binary cell fate choice
- (2016) Andre Olsson et al. NATURE
- Precision glycocalyx editing as a strategy for cancer immunotherapy
- (2016) Han Xiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
- (2015) Mingye Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
- (2014) Y. Pan et al. Science Translational Medicine
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
- (2013) Lei S. Qi et al. CELL
- Synthesis and Antimetastatic Effects ofE-Salignone Amide Derivatives
- (2013) Hong-Ling Wang et al. DRUG DEVELOPMENT RESEARCH
- Bruton's Tyrosine Kinase Is Required for Apoptotic Cell Uptake via Regulating the Phosphorylation and Localization of Calreticulin
- (2013) J. C. Byrne et al. JOURNAL OF IMMUNOLOGY
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
- (2013) W. W. Pang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- Macrophages: Gatekeepers of Tissue Integrity
- (2013) Y. Lavin et al. Cancer Immunology Research
- Primary phagocytosis of viable neurons by microglia activated with LPS or Aβ is dependent on calreticulin/LRP phagocytic signalling
- (2012) Michael Fricker et al. Journal of Neuroinflammation
- Programmed elimination of cells by caspase-independent cell extrusion in C. elegans
- (2012) Daniel P. Denning et al. NATURE
- Gene Expression Commons: An Open Platform for Absolute Gene Expression Profiling
- (2012) Jun Seita et al. PLoS One
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
- (2010) Andrew J. Gentles JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets
- (2010) Kosuke Yoshihara et al. PLoS One
- Macrophages as mediators of tumor immunosurveillance
- (2010) Siddhartha Jaiswal et al. TRENDS IN IMMUNOLOGY
- Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum
- (2009) Marek Michalak et al. BIOCHEMICAL JOURNAL
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
- (2009) B. J. Wouters et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer
- (2009) J. Joshua Smith et al. GASTROENTEROLOGY
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
- (2009) K. S. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
- (2008) M. H. Tomasson et al. BLOOD
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More